NCTN Myeloma Trials Portfolio (Open as of 5/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



NCTN Myeloma Trials (Open as of 5/15/2025)

Protocol Number	Phase	Protocol Title
		A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in
		Combination with Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin
A062101	1/11	(GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
		Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel
A062102	П	CAR-T in Multiple Myeloma Patients
		Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-
EAA173	ш	SMM)
		Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for
EAA181	ш	Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
		A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered
		Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed
S2209	ш	by Double or Single-Agent Maintenance
		A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone
		(Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and
S2213	Ш	Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis